Objectives: The incidence of Clostridium difficile infection (CDI) in adults with malignancy is 7%-14% compared with 1%-2% in the general hospitalized population. Despite the increased incidence of CDI in this population, a major concern is the propensity of CDI to recur, leading to delays in therapy impacting outcomes. We conducted a retrospective case-control study to identify risk factors for recurrent CDI (rCDI) and to determine the impact of rCDI on adult patients with a haematological malignancy.
Introduction
Over the past decade, Clostridium difficile, an anaerobic, Grampositive, spore-forming bacterium, has become the leading cause of nosocomial infections in the USA.
1-3 C. difficile infection (CDI) can be self-limiting or may progress to serious and life-threatening fulminant colitis, ileus or toxic megacolon. 4 In addition to this, CDI increases the duration of hospitalization and is responsible for an estimated $4.8 billion in excess healthcare costs in the USA. 5 The incidence of CDI is 1%-2% in the general hospitalized population and antibiotic exposure remains the leading risk factor for CDI. 1, 2 Over the last two decades, outbreaks of resistant C. difficile strains causing recurrent and remarkably severe CDI have increased in prevalence. 1, 2 Patients with cancer are at an increased risk of CDI because of their underlying malignancy, depressed immune response and exposure to chemotherapy. 2, [6] [7] [8] The incidence of CDI in haematology patients is 7%-14%, indicating that additional risk factors present in this population may contribute to the increased incidence of CDI. 9 Although the increased risk in both frequency and severity of CDI in haematology patients is significant, a major concern is the propensity of CDI to recur. 3, 10 Recent data indicate that the incidence of recurrent CDI (rCDI) is 15%-35% after discontinuation of therapy against CDI. 11 Management of rCDI is challenging and associated with higher morbidity, mortality and healthcare expenditures. 11 Despite the high risk of CDI acquisition and incidence of rCDI in haematology patients, there is a paucity of data analysing risk factors associated with rCDI for this specific patient population. 2, 11, 12 Several studies have identified risk factors for rCDI in the general hospitalized population. 10 These traditional risk factors included advanced age (65 years), duration of hospitalization (14 days), chronic renal insufficiency, elevated white blood cell count, low serum albumin, use of acid-suppression therapy and continued use of broad-spectrum antimicrobials. [13] [14] [15] [16] [17] However, these studies were limited because they lacked adequate data to V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
assess the impact of index CDI (iCDI) treatment and specific non-CDI antimicrobials. 10 Furthermore, these studies focused on factors immediately preceding rCDI onset, ignoring the possibility that factors near the onset of iCDI could have contributed to recurrence. 10 In adult haematology patients, a precise understanding of who is at a higher risk of developing rCDI is an important clinical question that currently lacks adequate data to assist clinicians in fully understanding rCDI risk factors. Data linking rCDI to modifiable risk factors would allow clinicians to avoid these exposures if possible and recognition of unmodifiable risk factors may lead to preventative strategies or targeted initial therapy.
Methods

Hospital
This retrospective study was conducted at the University of Michigan Health System (UMHS) in Ann Arbor, MI, a 1059 bed, tertiary-care, university-affiliated hospital with 47 000 admissions annually.
Ethics
Ethics approval was obtained from the Institutional Review Board (IRB) at the University of Michigan Health System (approval number HUM00106249). Written informed consent was waived by the IRB.
Study design
Adult (age 18 years) patients with an active haematological malignancy and CDI from June 2010 to December 2014 were identified from the electronic medical record (EMR) at UMHS and screened for inclusion in this retrospective case-control study. Patients who received an autologous or allogeneic HSCT were excluded from the study. Additionally, patients with inadequate follow-up (,6 months) from the iCDI at UMHS were also excluded.
Study data were collected using the EMR and managed using the Research Electronic Data Capture (REDCap TM ) tools hosted at UMHS. 18 Data collection points at iCDI included patient demographics, CDI severity, CDI treatment, CDI treatment duration, traditional CDI risk factors and potential haematology-specific risk factors. Traditional risk factors for CDI collected included age .65 years, antibiotic exposure, acid-suppressive therapy and history of CDI. Additional potential haematological risk factors that were evaluated included type of malignancy, neutropenia and duration of neutropenia at iCDI and chemotherapy exposure (regimen, duration and number of days prior to iCDI). All potential risk factor data at iCDI were collected starting 14 days prior to iCDI diagnosis. The study population was divided into two groups for analysis: recurrent CDI (rCDI) and non-recurrent CDI (non-rCDI); rCDI was defined as a repeat positive CDI occurring within 6 months after the end of treatment and cessation of symptoms for the iCDI. The 6 month time period for rCDI was chosen based on prior studies of risk factors for rCDI and patterns of recurrence risk over time. 2, [19] [20] [21] For patients with multiple CDIs, the earliest positive date was considered the iCDI and all subsequent positive CDIs 30 days after resolution of symptoms were considered recurrences. Longitudinal data were collected for 6 months after iCDI treatment was complete and symptoms resolved. Data collection points included traditional risk factors for CDI and haematological risk factors as listed above. Additionally, progress notes were reviewed for explanations justifying modifications to treatment plans, which included delays, dose reductions or discontinuation of chemotherapy. Acid-suppressive therapy was defined as use of a proton pump inhibitor (PPI) or histamine type-2 receptor antagonist (H2RA) for 2 days. History of CDI was a previous CDI 1 year from iCDI. Neutropenia was defined as an absolute neutrophil count (ANC) ,500 cells/mm 3 . CDI was classified as severe in patients with a white blood cell (WBC) count 15 000 cells/mm 3 or serum creatinine (SCr) 1.5% baseline SCr or evidence of ileus. Haematological malignancies included acute and chronic leukaemias, multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and myelodysplastic or myeloproliferative neoplasms.
Statistical analyses
Statistical analyses were performed using SPSS software, version 23.0 (SPSS, Inc., Chicago, IL, USA). Demographic data were analysed by descriptive statistics, continuous data were analysed by two-tailed Student's t-test and dichotomous data were analysed by Pearson's v 2 test or Fisher's exact test. Mann-Whitney U-tests were performed for non-normally distributed factors. Exploratory unconditional logistic regression analysis was performed to evaluate variables associated with rCDI. Variables with a P value 0.2 on univariate analysis were initially considered for inclusion in the multivariable model. For co-linear variables with a P value 0.2 on univariate analysis, only one variable was included in the multivariable model. Two separate regression models were created: one to assess possible iCDI risk factors associated with rCDI (forward conditional regression) and a second model to assess longitudinal risk factors associated with rCDI (binary regression). A receiver operating characteristic (ROC) curve was generated for both models to assess the sensitivity and specificity of the models. A P value of 0.05 was considered statistically significant and all P values were based on two-tailed tests.
Results
A total of 649 patients with CDI and malignancy were identified in the EMR from June 2010 to December 2014. Of these patients, 100 (15.4%) met the inclusion criteria ( Figure 1 ). During the 6 month follow-up, 41 patients (41.0%) developed rCDI and 59 (59.0%) did not develop rCDI. In the rCDI cohort, 30 patients (73.2%) had only one recurrence, whereas 11 patients (26.8%) experienced two or more episodes of rCDI ( Figure S1a , available as Supplementary data at JAC Online). The first recurrence of CDI occurred 30 days after the iCDI in 20 of the 41 patients with rCDI (48.9%). Among the remaining 21 patients, recurrences occurred after 31-60 days in 13 (31.7%) and 8 (19.5%) recurred .60 days but within 6 months after iCDI ( Figure S1b ).
Age, gender and race were not different between the two groups ( Table 1) . Metronidazole was used to treat 61.0% of the patients in the rCDI group compared with 45.8% of the patients in the non-rCDI group. The remaining patients were treated with oral vancomycin (19.5% rCDI versus 28.8% non-rCDI) or a combination of both agents (19.5% rCDI versus 25.4% non-rCDI) ( Table S1 ). The median duration of treatment was longer in the non-rCDI group for oral metronidazole and vancomycin, although this was not statistically significant (Table S1 ). Overall, antibiotic exposure and Recurrent CDI in haematology patients JAC use of acid-suppression therapy were not different between the two groups, although the non-rCDI group had more patients using combination PPI and H2RA than the rCDI group (18.0% versus 3.2%, P " 0.044).
Patients in the rCDI group had a significantly higher incidence of severe CDI (22.0% versus 6.8%, P " 0.027). Metronidazole was used to treat five of the patients in the rCDI group with severe CDI compared with two in the non-rCDI group. Oral vancomycin was used in two patients in the rCDI group with severe CDI and none in the non-rCDI group, whereas combination therapy was used in two patients in both groups. Median duration of treatment with oral metronidazole was 12 days (IQR [11] [12] [13] [14] [15] [16] [17] for the rCDI group with severe CDI compared with 15.5 days (IQR 10-21) in the nonrCDI group. Duration of combination therapy was numerically higher in the rCDI group with severe CDI (median 75 days, IQR 21-129 versus 34.5 days, IQR 12-57), but the difference was not statistically significant (Table S1) .
Differences in haematological data at iCDI were also compared on univariate analysis between the two groups. There was a significantly higher proportion of patients with AML in the non-rCDI group compared with the rCDI group (37.3% versus 17.1%, P " 0.028). NHL was the most common malignancy, followed by MM, ALL and CLL. At the time of iCDI, 72% of patients were receiving active chemotherapy (68.3% rCDI versus 74.6% non-rCDI, P " 0.491). iCDI occurred at a median of 9.5 days after chemotherapy in the rCDI group compared with 7.5 days in the non-rCDI group (P " 0.399). These were not different in the recurrent and non-recurrent groups. Other haematological data, including chemotherapy exposure and duration of neutropenia, were not statistically significantly different between the two groups at index on univariate analysis (Table 1) .
On multivariate analysis, exposure to salvage lymphoma regi-
at iCDI was the only independent haematological predictor of recurrent disease (OR 9.64, 95% CI 1.02-91.15, P " 0.048). Severe CDI at index was also shown to be an independent risk factor of rCDI (OR 4.82, 95% CI 1.31-17.66, P " 0.018) in this model. Many traditional risk factors for rCDI were present on univariate analysis (P 0.2); however, these differences were not shown to be significant on multivariable regression analysis ( Table 1 ). The ROC AUC for this model was 0.712 (95% CI 0.610-0.814).
Results of the univariate analysis during the 6 month follow-up revealed that patients in the rCDI group were hospitalized more (92.7% versus 62.7%, P " 0.001) and exposed to antibiotics more often than those in the non-rCDI group (85.4% versus 54.2%, P " 0.001). Antibiotic exposure was led by fluoroquinolones (58.4% versus 28.8%, P " 0.004) and b-lactams/b-lactamase inhibitors (68.3% versus 23.7%, P " 0.001). Additionally, the rCDI group was exposed to chemotherapy more often following iCDI (82.9% versus 62.7%, P " 0.028) than the non-rCDI group, including exposure to salvage lymphoma regimens (19.5% versus 3.4%, P " 0.014) ( Table 2) .
Multivariable analysis of longitudinal data was performed and an ROC curve with a high AUC was created. On multivariable analysis, exposure to fluoroquinolones (OR 3.96, 95% CI 1.04-15.15, P " 0.044), ceftriaxone (OR 18.93, 95% CI 1.27-281.95, P " 0.033) and piperacillin/tazobactam (OR 10.4, 95% CI 1.81-59.64, P " 0.009) were all associated with a significantly increased risk of rCDI ( Table 2 ). The duration of neutropenia was also identified as a statistically significant risk factor for rCDI on multivariable analysis (OR 0.94, 95% CI 0.89-0.98, P " 0.010), although in this case an increased duration of neutropenia was protective for rCDI. Additional possible haematology-specific risk factors identified on univariate analysis did not remain significant on multivariable analysis. The ROC AUC of the multivariable model was 0.870 (95% CI 0.802-0.938).
The impact of CDI on chemotherapy was also compared between the two groups. CDI impacted chemotherapy significantly more in the rCDI group compared with the non-rCDI group (53.7% versus 11.9%, P ,0.001). Among these patients, CDI primarily caused delays in initiation of subsequent cycles of chemotherapy. Delays in chemotherapy were statistically higher in the rCDI group (46.3% versus 10.3%, P ,0.001). Finally, chemotherapy was discontinued in one patient in both groups, and two patients in the rCDI group received a reduced dose due to the impact of CDI (Figure 2 ).
Discussion
The burden of CDI has significantly increased over the past decade.
1-3 Perhaps more concerning is the propensity for recurrence further impacting the patient and contributing to poor outcomes. A recent study by Olsen et al. 22 found that rCDI was associated with a significantly increased risk of death within 6 months of iCDI (36.3% versus 26.0%, P ,0.001). In our study, the rate of rCDI in haematology patients was remarkably high, at 41%. The higher recurrence rate of 41% may partially be explained by the 6 month time frame used to define recurrence in our analysis; however, similar studies examining the incidence of rCDI as far out as 6-12 months had significantly lower CDI recurrence rates of 23.2% and 22%, respectively. 2, 21 At 60 days, the recurrence rate in our study was 33.2%, which is significantly higher than the rate seen in the general hospitalized patients at our institution (9%) Scappaticci et al. Scappaticci et al.
and also higher than what has been seen in the literature to date. 4, 10, 11 To our knowledge, this is the first study to examine risk factors for rCDI in this population at iCDI and throughout a 6 month follow-up period. Identification of risk factors for recurrence may allow clinicians to proactively implement preventive strategies or targeted CDI treatment during the index episode.
In our study, exposure to salvage chemotherapy for lymphoma was found to be an independent risk factor for rCDI from the multivariable regression analysis at iCDI. The mechanism for this association is unclear. However, it is possible that the combination of underlying B cell dysfunction from malignancy and chemotherapies utilized in relapsed/refractory lymphomas suppresses the immune response, leaving the host at higher risk of recurrence. In a study by Kyne et al. 23 in 2001, serum antibody response measured on day 3 (IgM) and day 12 (IgG) against toxin A were significantly higher at iCDI in patients who did not develop rCDI. Another study, by Leav et al., 24 in 2009 confirmed these results, indicating the significance of humoral immunity in protecting hosts from rCDI. Because patients receiving salvage lymphoma regimens have received a significant amount of B cell depleting antibody therapy (e.g. rituximab) and have an increased exposure to traditional risk factors (e.g. hospitalization, antibiotics, etc.), it is possible that this contributes to high recurrence rates in this population.
A notable difference between the two groups on univariate and multivariate analyses was the higher frequency of severe CDI at index in the rCDI group. Several other prior studies have also demonstrated a higher risk of rCDI in patients with severe CDI on initial presentation. 21, 25 While not statistically significant, a higher percentage of patients in the rCDI group in general were treated with metronidazole and for a shorter duration of time; this was also observed in patients with severe CDI (Table S1 ). The higher frequency of recurrence in severe CDI patients may partially be explained by the treatment regimens used in this setting. Johnson et al. 26 conducted two identical, multicentre, prospective, randomized Phase 3 trials comparing metronidazole and vancomycin for CDI. The combined results showed a significantly higher treatment success with vancomycin (81.1% versus 72.7%, P " 0.020), which extended to patients with severe CDI (78.5% versus 66.3%, P ,0.001). Vancomycin also significantly lowered the rate of rCDI compared with metronidazole (20.6% versus 23%, P ,0.001).
26
Additional studies have had similar results. 27, 28 Thus, severe CDI at index may require more aggressive treatment with oral vancomycin and for potentially longer durations, in order to prevent recurrence.
Multivariate regression of longitudinal risk factors revealed exposure to fluoroquinolones, ceftriaxone and piperacillin/tazobactam as risk factors for rCDI. Our study adds to the current data correlating broad-spectrum antibiotics and hospitalizations with CDI and rCDI. 4, [13] [14] [15] [16] [17] 21 Additionally, an increased duration of neutropenia was found to be protective for rCDI at index and during the 6 month follow-up. Given that the depth and duration of neutropenia increase the risk of infection, these results were unexpected. 29, 30 A possible explanation for this is that more patients in the non-rCDI group were treated with oral vancomycin at index, including those that were neutropenic (Table S1 ). Furthermore, overall median treatment duration for the rCDI cohort was shorter in comparison with the non-rCDI cohort (Table 1) .
In clinical practice at our institution, patients with acute leukaemia who are neutropenic, on antibiotic prophylaxis/treatment and develop CDI are treated with oral vancomycin. Treatment continues for at least the duration of antibiotics and neutropenia, and often 7 days beyond antibiotic exposure. Despite being a high-risk population for CDI, we found a lower recurrence rate in our AML cohort compared with non-AML patients (24.1% versus 47.9%, P " 0.043). 31 This discrepancy on univariate analysis could be due to differences in both the agent selected and the duration of iCDI treatment. Beyond the known benefit of oral vancomycin compared with metronidazole for severe CDI, we discovered that patients with AML were treated significantly longer compared with those without AML [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) versus 14 days (12.5-22), P " 0.001]. [27] [28] [29] Furthermore, patients with AML treated with oral vancomycin had a recurrence rate of only 14.3% compared with 33.3% with metronidazole (P " 0.3898). In addition to the agent itself, the lower recurrence rate seen with oral vancomycin may be explained by the increased duration of therapy compared with metronidazole [median 27 (IQR 19-42) versus 18 days (IQR 14-21), P " 0.093] (Figure 3 ). Although our study was not designed to detect this difference, the protective effect of long durations of neutropenia may simply reflect both the preferential use of oral vancomycin and the extended therapy, as seen in patients with AML. Compared with other haematological malignancies (e.g. lymphoma), the duration of neutropenia is shorter and the incidence of febrile neutropenia is lower, decreasing exposure to antibiotic prophylaxis/treatment. In this setting, use of oral vancomycin for an extended duration of CDI treatment is not standard practice.
A significant finding in our study was the profound impact of rCDI on malignancy treatment. In the rCDI cohort, CDI impacted 53.7% of the established chemotherapy treatment plans, compared with only 11.9% of patients in the non-rCDI cohort. The majority of patients experienced a delay in therapy; however, a small proportion of patients required dose reductions and/or discontinuation of therapy. Although it was not feasible to evaluate the impact of cycle delays on malignancy progression and survival in this particular study, other studies have demonstrated the significant impact of cycle delays and relative dose intensity on outcomes, particularly in the curative setting. [32] [33] [34] Thus, recognition of risk factors for rCDI and modification of therapy may have serious implications for treatment outcomes.
There were several limitations to our study. First, given the retrospective nature of this study, it is difficult to account for all possible confounders that may impact rCDI. Possible confounders include admissions to other hospitals or prescriptions written by outside physicians. Second, because this was a single-centre study, risk factors identified at UMHS may differ from those at other institutions. Third, although our study showed that CDIs have a significant impact on chemotherapy, given the variety of haematological malignancies represented and the limited sample size we were not able to evaluate whether this translated into worse progression-free or overall survival.
Because of the extremely high recurrence rate in the entire cohort of haematology patients and the clear impact rCDI had on delivery of chemotherapy, one could argue that all haematology patients may require alternative management of iCDI. In our study, there was a distinct trend towards a lower incidence of rCDI in patients receiving oral vancomycin for longer durations. Classifying haematology patients as severe CDI and treating them Recurrent CDI in haematology patients JAC with oral vancomycin in line with IDSA guidelines may be a reasonable first step in decreasing the burden of rCDI in this population. 35 Based on our results, extending the treatment of iCDI to 28 days with oral vancomycin may reduce rCDIs. Further studies are necessary to appropriately evaluate this recommendation as our results are limited by our small sample size. Finally, use of novel agents such as fidaxomicin, bezlotoxumab or faecal material transplant (FMT) could potentially reduce rCDI in high-risk haematology patients, although data regarding their efficacy in this population are limited.
In conclusion, this study revealed a very high risk of rCDI in haematology patients. At iCDI, treatment with salvage chemotherapy for lymphoma and severe CDI were independent risk factors for developing rCDI. Risk factors identified during the 6 month follow-up included exposure to fluoroquinolones, ceftriaxone and piperacillin/tazobactam, whereas increased duration of neutropenia was found to reduce rCDIs. Patients with the aforementioned risk factors for rCDI may be appropriate for targeted use of novel CDI therapies, extended durations of iCDI therapy or CDI prophylaxis. Given the significantly higher impact on chemotherapy in the rCDI group, further studies are needed to delineate the optimal therapeutic approach in haematology patients at high risk of rCDI.
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